SNTI

Senti Biosciences Holdings, Inc. - 10-Q Summary (Q1 2025)

Business Context and Reporting Period

Senti Biosciences, Inc. (SNTI) is a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary gene circuit platform. The company focuses on oncology indications, with lead candidates SENTI-202 (blood cancers) and SENTI-301A (solid tumors). This report covers the quarterly period ended March 31, 2025. The company is classified as a non-accelerated filer, a smaller reporting company, and an emerging growth company.

Key Financial Metrics

Material Changes vs. Prior Period

• Net Loss Increase: Net loss increased by $2.0 million compared to Q1 2024, primarily driven by a decrease in "Other Income" due to the absence of fair value gains on the GeneFab Option and Note Receivable, which were present in the prior year.
• Operating Expenses: Total operating expenses remained relatively flat ($16.4M vs $16.3M). R&D expenses increased by $0.5 million due to higher external services and supplies, partially offset by lower personnel costs. G&A expenses decreased by $0.4 million.
• Other Income Decline: Total other income dropped from $4.2 million to $2.3 million. The prior year included a $2.3 million gain from the change in fair value of the GeneFab Option, which was zero in Q1 2025. Additionally, the GeneFab Note Receivable was waived in December 2024, eliminating related fair value adjustments.
• Capital Structure: In March 2025, the company converted 21,157 shares of Series A redeemable convertible preferred stock into 21,157,000 shares of common stock. As of March 31, 2025, no preferred stock remained outstanding.
• Cash Burn: Cash and cash equivalents decreased by approximately $14.5 million during the quarter, reflecting the net loss and operating cash outflows.

Guidance, Outlook, Risks, and Unusual Items

• Going Concern: Management has concluded that there is substantial doubt about the company's ability to continue as a going concern for at least one year from the issuance date. Cash on hand ($33.8 million) is deemed insufficient to fund operations for the next 12 months without additional financing.
• Clinical Updates:
  • SENTI-202: Preliminary Phase 1 data was announced in April 2025 for the treatment of relapsed/refractory hematologic malignancies.
  • SN301A: The partner, Celest Therapeutics, stopped dosing in the SN301A clinical trial in China in April 2025 due to observed dose-limiting toxicities.
• Financing Activities:
  • Terminated the Common Stock Purchase Agreement with Chardan Capital Markets on March 17, 2025.
  • Entered into a new At-The-Market (ATM) offering agreement with Leerink Partners on March 20, 2025, allowing for the sale of up to $17.5 million of common stock. No shares were sold under this agreement in Q1 2025.
  • Received $1.5 million in proceeds from a CIRM Grant in Q1 2025.
• Internal Controls: The company identified a material weakness in internal control over financial reporting related to insufficient resources in the finance and accounting function. This weakness has not been fully remediated as of March 31, 2025.
• Related Party Transactions: Significant transactions with GeneFab (related party) include sublease income ($1.7 million) and prepaid expenses ($6.6 million). The GeneFab Note Receivable was waived in late 2024.

Investor Verification Checklist

• Liquidity Runway: Verify the timeline and terms of potential future capital raises given the "substantial doubt" going concern disclosure.
• SN301A Impact: Assess the strategic and financial implications of the halted SN301A trial due to toxicity and the status of the partnership with Celest Therapeutics.
• Internal Control Remediation: Monitor progress on hiring and training to remediate the material weakness in financial reporting controls.
• ATM Utilization: Track the utilization of the new $17.5 million ATM facility with Leerink Partners to gauge immediate capital raising efforts.
• GeneFab Dependency: Review the terms of the manufacturing and sublease agreements with GeneFab, particularly regarding the $6.6 million in prepaid expenses and the waiver of the note receivable.